期刊文献+

长期小剂量阿托伐他汀联合非诺贝特对颈动脉粥样硬化的影响 预览

Effect of Long-term Low Dose Atorvastatin Combined with Fenofibrate on Lipid Regulation and Carotid Atherosclerosis
在线阅读 下载PDF
收藏 分享 导出
摘要 目的:观察小剂量阿托伐他汀联合非诺贝特对冠心病、冠心病等危征、代谢综合征等患者颈动脉粥样硬化内中膜厚度(IMT)及血脂成分的影响。方法:冠心病、冠心病等危征及代谢综合征患者82例,随机分为联合用药组及对照组,对照组单纯给与阿伐托拉丁治疗,联合用药组加用非若贝特治疗,共12月;彩色超声检查两组患者治疗前后颈动脉IMT、斑块数量及斑块稳定性,对IMT值与总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白(HDL-C)、低密度脂蛋白(LDL-C)及脂蛋白a(apo-A)进行相关性分析。结果:治疗后联合用药组IMT减小,斑块数量及不稳定斑块数量减少(P<0.05),对照组3项指标与治疗前比较无显著变化(P>0.05);相关性分析结果显示,IMT与血清中TC、TG、LDL及apo-A正相关,与HDL负相关。结论:长期小剂量阿托伐他汀联合非诺贝特治疗冠心病、冠心病危象及代谢综合征患者可以减缓颈动脉粥样硬化病变进程。 Objective:To examine the effects of low-dose atorvastatin combined with fenofibrate on intima-media thickness(IMT)of carotid atherosclerosis and lipid composition in patients with coronary heart disease(CHD),or CHD risk equivalents or other metabolic syndromes.Methods:82 patients with CHD,or CHD risk equivalents,or other metabolic syndromes were randomly divided into the combination group and the control group.The control group was given 10 mg apratolide alone,and the combination group was treated with 10 mg apratolide plus 200 mg fenofibrate.The treatment lasted 12 months.Color ultrasound was used to examine carotid IMT,plaque number and plaque stability before and after treatment.The correlation of IMT value with total cholesterol(TC),triglyceride(TG),high density lipoprotein(HDL-C),low-density lipoprotein(LDL-C)and lipoprotein a(apo-A)were analyzed.Results:The combination treatment significantly decreased the IMT values,the number of plaques and the number of unstable plaques(P<0.05),but apratolide alone did not significantly influence these three indexes in control group(P>0.05).The correlation analysis showed that IMT is positively correlated with serum TC,TG,LDL and apo-A,but negatively correlated with HDL.Conclusion:Long-term low-dose atorvastatin combined with fenofibrate can reduce the progression of carotid atherosclerosis in patients with CHD,or CHD risk equivalents,or other metabolic syndrome.
作者 吕颖 张军波 刘仲伟 韩稳琦 程曼丽 赵朝 LV Ying;ZHANG Junbo;LIU Zhongwei;HAN Wenqi;CHENG Manli;ZHAO Chao(Department of Cardiovascular Medicine,the Third Affiliated Hospital of Xi'an Jiaotong University,Shaanxi Provincial People's Hospital,Xi'an 710068,Shaanxi,China;Department of Cardiovascular Medicine,The First Affiliated Hospital of Medical College of Xi'an Jiaotong University,Xi'an 710061,Shaanxi,China;Department of Cardiovascular Medicine,Xi'an No. 1 Hospital,Xi'an 710002,Shannxi,China)
出处 《贵州医科大学学报》 CAS 2019年第7期833-837,共5页 Journal of Guizhou Medical University
基金 国家自然科学基金项目(81600646).
关键词 动脉粥样硬化 调血脂药 非诺贝特 阿托伐他汀 颈动脉内中膜厚度 atherosclerosis lipid-regulating drug fenofibrate atorvastatin carotid intima-media thickness
作者简介 通信作者:张军波,E-mail:bobzjb@163.com.
  • 相关文献

参考文献4

二级参考文献50

  • 1姜妮,苏津自,许昌声,林金秀.非诺贝特对自发性高血压大鼠颈动脉球囊损伤后内膜增生的影响[J].中华高血压杂志,2006,14(9):715-718. 被引量:8
  • 2AI-Lawati JA, AI-Hinai HQ, Mohammed AJ, et al. Prevalence of the metabolic syndrome among Omani adults. Diabetes Care,2003,26: 1781-1785. 被引量:1
  • 3Santos AC, Lopes C, Barros H. Prevalence of metabolic syndrome in the city of Porto. Rev Port Cardiol, 2004, 23 : 45-52(abstract reviewonly). 被引量:1
  • 4Bonora E, Targher G, Formentini G, et al. The metabolic syndrome is an independent predictor of cardiovascular disease in type 2 diabetic subject. Prospective data from the Verona Diabetes Complications Study. Diabetic Med,2003, 21 : 52-58. 被引量:1
  • 5Jia WP, Lu JX, Xlang KS, et al. Prediction of abdominal visceral obesity from body mass index, waist.circumference and waist-hip ratio in Chinese adults: receiver operating characteristic curve analysis. Biomed Environ Sci,2003, 161206-211. 被引量:1
  • 6Gaede P Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. New Eng J Med,2003, 348: 383-393. 被引量:1
  • 7Panzer C, Brieke A, Ruderman N. Prevention of type 2 diabetes and its macrovascular complications., whom, when, and how should we treat? Current Opin Endocrinol Diabetes, 2003, 10:229-236. 被引量:1
  • 8Lord JM, Flight IHK, Norman RJ. Metformin in polycystic ovary syndrome, systematic review and meta analysis. BMJ,2003, 327:951-956. 被引量:1
  • 9Girman CJ, Rhodes T, Mercuri M, et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/ Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS).Am J Cardiol,2004, 93:136-141. 被引量:1
  • 10Pyorala K, Ballantyne C, Lee M, et al. Reduction of coronary events by simvastatin in non-diabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analysis of the Scandinavian Simvastatin Survival Study (4S).Diabetes,2003, 52 (s1) : A19. 被引量:1

共引文献2375

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈